Comparative Pharmacology
Head-to-head clinical analysis: ALORA versus ESTRADIOL CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALORA versus ESTRADIOL CYPIONATE.
ALORA vs ESTRADIOL CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
1-5 mg intramuscularly every 3-4 weeks.
None Documented
None Documented
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Category C
Category D/X
Estrogen
Estrogen